Benefits
NAFLD/MASLD adjunct — strongest evidence base
In non-alcoholic fatty liver disease, phosphatidylcholine at 1.8-2.1 g/day for 6 months significantly improves liver enzymes — ALT normalization rates roughly double in supplemented patients. Effect is consistent across observational and randomized trials, with positive results in patients also managing diabetes, hyperlipidemia, or obesity. Reasonable adjunct for NAFLD/MASLD management alongside dietary changes. Listed in NAFLD treatment guidelines in some countries (Russia, several European).
Liver fibrosis improvement — preliminary
PC at 2,100 mg/day for 6 months in NAFLD patients shows measurable improvements in fibrosis scores (FibroScan) and steatosis severity beyond liver enzyme reduction. Suggests the benefit extends to actual tissue improvement, not just lab values. Effect is preliminary — needs larger replication — but the directional signal is meaningful given how few interventions show measurable fibrosis improvement. Reasonable consideration in NAFLD with fibrosis under hepatology guidance.
Ulcerative colitis — popular claim, NOT validated
PC was a promising candidate for ulcerative colitis based on the observation that PC content in colonic mucus is reduced in UC patients. Early phase 2 trials of modified-release PC (LT-02) showed encouraging results. However, the definitive phase 3 trials (PROTECT-1 and PROTECT-3) were terminated early for futility — PC failed to induce remission. Honest framing: PC for UC is NOT validated despite earlier positive signals. The mechanism didn't translate to clinical efficacy at scale.
Cognitive function — choline pathway
PC is a major dietary form of choline, the precursor to acetylcholine — the neurotransmitter most associated with memory and attention. Adequate choline intake is associated with better cognitive outcomes in observational studies, particularly in aging. Specific RCT evidence that PC supplementation improves cognition in healthy adults is limited. For cognitive applications specifically, alpha-GPC and citicoline have stronger direct evidence than PC.
Pregnancy choline support
Choline requirements increase substantially during pregnancy and lactation (450-550 mg/day recommended). Most prenatal vitamins contain inadequate choline relative to this requirement. PC supplementation can help close the gap, and maternal choline supplementation has been shown to improve offspring cognitive outcomes. Practical alternative: dietary sources like eggs and fish work equally well — choose PC supplementation if dietary choline intake is genuinely low.
Cardiovascular markers — uncertain net effect
PC may modestly support HDL cholesterol levels through its role in lipoprotein biology. However, choline metabolism by gut bacteria produces TMAO, and elevated TMAO has been associated with increased cardiovascular risk in observational studies. Net cardiovascular impact is uncertain — TMAO concerns may offset direct lipid benefits. Honest framing: don't supplement PC for cardiovascular reasons specifically; the evidence is too mixed to make a clear case either way.
Cell membrane and gut barrier biology
PC is the most abundant phospholipid in human cell membranes and a major component of intestinal mucus that protects the gut lining. Mechanistic basis for liver and gut applications is solid — but as the failed UC trials show, mechanistic plausibility doesn't always translate to clinical efficacy. Most relevant for liver indications where the mechanism-to-outcome link has been validated; less reliable for gut indications despite the underlying rationale.
Mechanism of action
Cell membrane component
PC is the most abundant phospholipid in cell membranes — comprising approximately 50% of total membrane phospholipid in most cell types. Maintains membrane fluidity, supports embedded protein function (receptors, channels, enzymes), and serves as substrate for signaling lipid generation.
Choline source for acetylcholine synthesis
PC catabolism releases free choline, which crosses the blood-brain barrier and serves as substrate for acetylcholine synthesis via choline acetyltransferase. Acetylcholine is critical for memory, learning, and neuromuscular function. PC is the major dietary choline form (eggs, lecithin, fish, dairy).
VLDL formation and hepatic lipid export
PC is essential for assembly and secretion of very-low-density lipoproteins (VLDL) — the primary mechanism of hepatic triglyceride export. Choline/PC deficiency impairs VLDL formation, leading to triglyceride accumulation in hepatocytes (steatosis). This is the molecular basis for PC's role in NAFLD/MASLD.
Intestinal mucus hydrophobic barrier
PC is a key component of colonic mucus, providing the hydrophobic surfactant-like barrier protecting epithelium from microbiota and luminal contents. Reduced mucosal PC content is observed in ulcerative colitis — providing the mechanistic rationale for PC supplementation that ultimately failed in phase 3 trials.
Anti-inflammatory effects
PC and its metabolites modulate inflammatory signaling, partly through TLR-2 modulation and downstream NF-κB inhibition. Lysophosphatidylcholine intermediates have complex inflammatory effects depending on fatty acid composition. Anti-inflammatory mechanism is one factor in NAFLD/MASLD efficacy beyond direct steatosis effects.
Clinical trials
Russian observational registry study, n=2,843 NAFLD patients with metabolic comorbidities receiving polyenylphosphatidylcholine 1.8 g/day × 24 weeks. ALT normalization: 36.2% → 75.8%. AST normalization: 52.3% → 89.2%. GGT normalization: 39.8% → 62.5%. Caveat: observational design, not placebo-controlled. Real-world signal driving subsequent randomized trials.
Randomized double-blind placebo-controlled phase IV trial in MASLD patients with type 2 diabetes, hyperlipidemia, or obesity. Essential phospholipids (EPL) significantly improved hepatic steatosis vs placebo. Better-quality contemporary evidence than the earlier observational/Russian trials. Strengthens the case for PC as MASLD adjunct therapy.
Phase 3 trials of LT-02 modified-release PC in mesalamine-refractory ulcerative colitis. PROTECT-1 induction trial TERMINATED early for futility per IDMC recommendation. PROTECT-3 also terminated — 'LT-02 did not appear to help induce remission of UC.' PROTECT-2 maintenance phase signal remains uncertain. Major reset of UC indication after promising Stremmel 2007 phase 2 results.
Earlier phase 2 RCT in 60 patients with steroid-refractory chronic ulcerative colitis. Delayed-release PC achieved clinical remission in significantly more patients than placebo. These promising phase 2 findings led to the phase 3 PROTECT trial program — which subsequently failed at scale. Important historical context for understanding the negative phase 3 outcomes.
RCT of maternal choline supplementation during third trimester. Higher choline intake (930 mg/day vs 480 mg/day) improved offspring information processing speed at 4, 7, 10, and 13 months. Supports choline (PC is a major form) requirements during pregnancy. Most prenatal vitamins under-deliver on choline relative to recommendations.